Breaking News Instant updates and real-time market news.

BMY

Bristol-Myers

$54.31

-1.7 (-3.04%)

12:30
10/21/18
10/21
12:30
10/21/18
12:30

Opdivo, Yervoy combo shows promising results in advanced form of bladder cancer

Bristol-Myers Squibb announced follow-up data evaluating Opdivo monotherapy and Opdivo in combination with Yervoy in patients with platinum-pretreated metastatic urothelial carcinoma. Results from the Phase 1/2 CheckMate -032 trial showed that patients who received the combination of Opdivo 1 mg/kg plus Yervoy 3 mg/kg experienced a higher objective response rate compared to those who received Opdivo 3 mg/kg plus Yervoy 1 mg/kg or Opdivo alone. Patients in the study were heavily pretreated, with most receiving at least two prior treatment regimens. At a minimum follow-up of 7.9 months for the expanded cohort of patients receiving O1:Y3, the ORR was 38%. For patients receiving O3:Y1, at a minimum follow-up of 38.8 months the ORR was 27%, and for patients receiving Opdivo alone, at a minimum follow-up of 37.7 months the ORR was 26%. Median progression-free survival and overall survival, secondary endpoints in the study, were numerically longer in the O1:Y3 treatment cohort compared to the O3:Y1 and Opdivo monotherapy cohorts. The overall safety profile was consistent with prior studies of Opdivo in combination with Yervoy with these dosing schedules. Grade 3 or 4 treatment-related adverse events occurred in 27%, 31% and 39% of patients treated with Opdivo monotherapy, O3:Y1 and O1:Y3, respectively; grade 5 TRAEs were observed in one patient each in the Opdivo monotherapy and O3:Y1 groups; no grade 5 TRAEs were observed in the O1:Y3 group. The combination of Opdivo plus Yervoy was also well tolerated, with 13% discontinuation rate due to TRAEs in the O1:Y3 group and 13% discontinuation rate in the O3:Y1 group. The discontinuation rate due to TRAEs in the Opdivo monotherapy group was 4%.

  • 22

    Oct

  • 25

    Oct

  • 29

    Oct

  • 07

    Nov

BMY Bristol-Myers
$54.31

-1.7 (-3.04%)

10/16/18
WELS
10/16/18
NO CHANGE
WELS
Drug price in ads not impactful, may cause confusion, says Wells Fargo
Wells Fargo analyst David Maris acknowledges that the U.S. Department of Health and Human Services' proposal to include drug prices in advertisements has a "noble goal" of making drugs more affordable and keeping patients well informed. However, given how different list prices are relative to out of pocket costs, "one must ask if this is increasing transparency or likely going to lead to more confusion," he contends. The analyst also believes that the unintended consequence could be worse care, while noting that the drug price information will likely fall into the category of the side effect information in drug ads currently, tuned out by many and will have no material impact. While he supports the idea of increased transparency, Maris wonders whether the potential benefit is not outweighed by the potential negative for the most vulnerable. Publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
10/08/18
GUGG
10/08/18
INITIATION
Target $70
GUGG
Neutral
Bristol-Myers initiated with a Neutral at Guggenheim
Guggenheim analyst Seamus Fernandez started Bristol-Myers with a Neutral rating and $70 price target, contending that near-term Opdivo catalysts are largely in the stock. He sees the risk-reward as being balanced ahead of several trial read outs in 2019 from Bristol and its competitors, Fernandez added.
09/12/18
FBCO
09/12/18
NO CHANGE
FBCO
Neutral
Bristol-Myers' TYK2 efficacy looks better than Otezla, says Credit Suisse
After Bristol-Myers (BMY) presented Phase 2 data for its oral TYK2 inhibitor, BMS-986165, in moderate-to-severe psoriasis at the EAVD meeting, Credit Suisse analyst Vamil Divan said he believes the "robust" data are very encouraging for the ongoing Phase 3 studies. BMS-986165 achieved PASI 75 response rates that are better than what was demonstrated by Celgene's (CELG) Otezla and the safety profile "appears reasonable," Divan tells investors. While BMS-986165 could be highly competitive clinically against other oral treatments, the crowded psoriasis market remains a tough one for new products, added the analyst, who keeps a Neutral rating on Bristol-Myers shares.
09/06/18
MSCO
09/06/18
NO CHANGE
Target $63
MSCO
Equal Weight
Bristol-Myers' TYK2 inhibitor may be underappreciated asset, says Morgan Stanley
Morgan Stanley analyst David Risinger said that Phase 2 data on Bristol-Myers' oral TYK2 inhibitor BMS-986165 will be presented at the EADV meeting on Wednesday September 12, adding that it could be an underappreciated asset if it offers better efficacy than other oral drugs and is safer. To his knowledge, no JAK inhibitors are currently being developed for psoriasis, Risinger noted. The analyst, who said 986165 "theoretically has blockbuster potential," maintains an Equal Weight rating on Bristol shares as further Opdivo lung newsflow is awaited.

TODAY'S FREE FLY STORIES

MGM

MGM Resorts

$28.92

-0.14 (-0.48%)

, BX

Blackstone

$52.46

-0.45 (-0.85%)

15:00
09/20/19
09/20
15:00
09/20/19
15:00
Periodicals
MGM Resorts in talks to sell Circus Circus casino to Phil Ruffin, Bloomberg says »

MGM Resorts (MGM) is in…

MGM

MGM Resorts

$28.92

-0.14 (-0.48%)

BX

Blackstone

$52.46

-0.45 (-0.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

TGT

Target

$107.36

-0.48 (-0.45%)

15:00
09/20/19
09/20
15:00
09/20/19
15:00
Options
Buyer pays 12c over parity for deep in the money expiring Sep 87.5 calls »

Buyer pays 12c over…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

CAG

Conagra Brands

$29.95

0.3 (1.01%)

14:55
09/20/19
09/20
14:55
09/20/19
14:55
Options
ConAgra put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 01

    Oct

14:50
09/20/19
09/20
14:50
09/20/19
14:50
General news
Fed's Kaplan said he backed the Fed's rate cuts in September and July »

Fed's Kaplan said he…

FB

Facebook

$189.71

-0.44 (-0.23%)

14:48
09/20/19
09/20
14:48
09/20/19
14:48
Hot Stocks
Facebook says has suspended 'tens of thousands' of apps over data use »

In a blog post, Facebook…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 24

    Sep

  • 27

    Oct

SKT

Tanger Factory

$15.90

0.13 (0.82%)

14:35
09/20/19
09/20
14:35
09/20/19
14:35
Options
Tanger Factory put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:35
09/20/19
09/20
14:35
09/20/19
14:35
General news
Action Economics Survey results: »

Action Economics Survey…

USAT

USA Technologies

$7.43

-0.22 (-2.88%)

14:31
09/20/19
09/20
14:31
09/20/19
14:31
Hot Stocks
Breaking Hot Stocks news story on USA Technologies »

USA Technologies trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USAT

USA Technologies

$7.43

-0.22 (-2.88%)

14:28
09/20/19
09/20
14:28
09/20/19
14:28
Hot Stocks
USA Technologies says unlikely to meet Nasdaq deadline for filing compliance »

USA Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USAT

USA Technologies

$7.43

-0.22 (-2.88%)

14:26
09/20/19
09/20
14:26
09/20/19
14:26
Hot Stocks
Breaking Hot Stocks news story on USA Technologies »

USA Technologies trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FISV

Fiserv

$104.82

-0.03 (-0.03%)

14:25
09/20/19
09/20
14:25
09/20/19
14:25
Options
Fiserv call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

  • 27

    Oct

TD

Toronto-Dominion

$57.97

0.4 (0.69%)

, DB

Deutsche Bank

$8.02

-0.055 (-0.68%)

14:24
09/20/19
09/20
14:24
09/20/19
14:24
Hot Stocks
TD accepted Epstein accounts after Deutsche cut ties, Bloomberg says »

Canadian lender…

TD

Toronto-Dominion

$57.97

0.4 (0.69%)

DB

Deutsche Bank

$8.02

-0.055 (-0.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

IVV

iShares Core S&P 500

$301.93

-0.845 (-0.28%)

, SPY

SPDR S&P 500 ETF Trust

$298.77

-0.906381 (-0.30%)

14:22
09/20/19
09/20
14:22
09/20/19
14:22
Technical Analysis
On The Fly: Weekly technical notes for S&P 500 »

ETF fund flows to the top…

IVV

iShares Core S&P 500

$301.93

-0.845 (-0.28%)

SPY

SPDR S&P 500 ETF Trust

$298.77

-0.906381 (-0.30%)

HYG

iShares iBoxx $ High Yield Corporate Bond

$87.41

0.05 (0.06%)

IEF

iShares 7-10 Year Treasury Bond ETF

$111.69

0.335 (0.30%)

ITE

SPDR Bloomberg Barclays Intermediate Term Treasury ETF

$62.19

0.065 (0.10%)

SPTL

SPDR Portfolio Long Term Treasury ETF

$40.45

0.12 (0.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

14:17
09/20/19
09/20
14:17
09/20/19
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

14:16
09/20/19
09/20
14:16
09/20/19
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PDD

Pinduoduo

$33.65

-0.98 (-2.83%)

14:15
09/20/19
09/20
14:15
09/20/19
14:15
Options
Pinduoduo put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FIT

Fitbit

$4.00

0.3347 (9.13%)

14:11
09/20/19
09/20
14:11
09/20/19
14:11
Periodicals
Fitbit deciding whether to explore sale, Reuters says »

Fitbit (FIT) has held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FIT

Fitbit

$3.69

0.025 (0.68%)

14:07
09/20/19
09/20
14:07
09/20/19
14:07
Hot Stocks
Fitbit rises after report of hiring bank to consider sale »

Shares of Fitbit are…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FIT

Fitbit

$3.73

0.06 (1.64%)

14:03
09/20/19
09/20
14:03
09/20/19
14:03
Periodicals
Breaking Periodicals news story on Fitbit »

Fitbit in talks with bank…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

W

Wayfair

$122.80

-5.865 (-4.56%)

13:55
09/20/19
09/20
13:55
09/20/19
13:55
Options
Wayfair put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DELL

Dell Technologies

$52.26

-0.8 (-1.51%)

13:53
09/20/19
09/20
13:53
09/20/19
13:53
Conference/Events
Dell Technologies to hold a business news update meeting »

CFO Sweet, along with SVP…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 26

    Nov

FTR

Frontier Communications

$1.00

-0.0006 (-0.06%)

13:43
09/20/19
09/20
13:43
09/20/19
13:43
Periodicals
Frontier Communications prepares for debt restructuring talks, WSJ reports »

Frontier Communications…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:40
09/20/19
09/20
13:40
09/20/19
13:40
General news
U.S. equity markets »

U.S. equity markets were…

BTU

Peabody Energy

$15.47

-1.56 (-9.16%)

, ARCH

Arch Coal

$71.00

-5.37 (-7.03%)

13:39
09/20/19
09/20
13:39
09/20/19
13:39
Hot Stocks
Peabody Energy confirms commitment to pending PRB/Colorado joint venture »

Peabody (BTU) confirmed…

BTU

Peabody Energy

$15.47

-1.56 (-9.16%)

ARCH

Arch Coal

$71.00

-5.37 (-7.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

SPY

SPDR S&P 500 ETF Trust

$298.09

-1.586381 (-0.53%)

, SPX

S&P 500

$0.00

(0.00%)

13:34
09/20/19
09/20
13:34
09/20/19
13:34
Periodicals
Chinese delgation cancels farm trip to Montana, Reuters reports »

Chinese officials that…

SPY

SPDR S&P 500 ETF Trust

$298.09

-1.586381 (-0.53%)

SPX

S&P 500

$0.00

(0.00%)

DJX

Dow Jones Industrial Average

$0.00

(0.00%)

NDX

Nasdaq 100 Index

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.